Free Trial
Final Hours! Save $100 on MarketBeat All Access Before 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion

Tyra Biosciences (TYRA) Financials

Tyra Biosciences logo
$32.47 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$32.46 -0.02 (-0.05%)
As of 05/22/2026 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Tyra Biosciences

Annual Income Statements for Tyra Biosciences

This table shows Tyra Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -9.34 -26 -55 -69 -86 -120
Consolidated Net Income / (Loss)		 -9.34 -26 -55 -69 -86 -120
Net Income / (Loss) Continuing Operations		 -9.34 -26 -55 -69 -86 -120
Total Pre-Tax Income 		-9.34 -26 -55 -69 -86 -120
Total Operating Income		 -9.30 -26 -59 -80 -104 -133
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 9.30 26 59 80 104 133
Selling, General & Admin Expense		 2.09 5.65 16 17 24 30
Research & Development Expense		 7.20 21 43 63 80 103
Total Other Income / (Expense), net		 -0.04 -0.01 3.60 11 18 13
Interest & Investment Income		 -0.00 0.01 3.65 11 18 13
Basic Earnings per Share		 ($6.05) ($1.91) ($1.32) ($1.62) ($1.51) ($2.01)
Weighted Average Basic Shares Outstanding		 1.54M 13.78M 41.88M 42.70M 57.22M 59.60M
Diluted Earnings per Share		 ($6.05) ($1.91) ($1.32) ($1.62) ($1.51) ($2.01)
Weighted Average Diluted Shares Outstanding		 1.54M 13.78M 41.88M 42.70M 57.22M 59.60M
Weighted Average Basic & Diluted Shares Outstanding		 1.54M 13.78M 42.44M 52.52M 53.09M 53.87M

Quarterly Income Statements for Tyra Biosciences

This table shows Tyra Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -21 -22 -18 -19 -24 -27 -28 -28 -30 -34 -39
Consolidated Net Income / (Loss)		 -21 -23 -18 -19 -24 -26 -28 -28 -30 -34 -39
Net Income / (Loss) Continuing Operations		 -21 -23 -18 -19 -24 -26 -28 -28 -30 -34 -39
Total Pre-Tax Income 		-21 -23 -18 -19 -24 -26 -28 -28 -30 -34 -39
Total Operating Income		 -24 -26 -22 -24 -29 -30 -32 -31 -33 -37 -42
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 24 26 22 24 29 30 32 31 33 37 42
Selling, General & Admin Expense		 4.69 4.96 5.12 5.54 5.91 7.54 6.89 7.14 7.48 8.33 8.53
Research & Development Expense		 19 21 17 18 23 22 25 24 25 28 33
Total Other Income / (Expense), net		 2.81 2.80 4.13 4.83 4.59 4.15 3.70 3.35 3.08 2.68 2.69
Interest & Investment Income		 2.81 2.80 4.13 4.83 4.59 4.15 3.70 3.35 3.08 2.68 2.69
Basic Earnings per Share		 ($0.49) ($0.54) ($0.35) ($0.32) ($0.41) ($0.43) ($0.47) ($0.47) ($0.50) ($0.57) ($0.64)
Weighted Average Basic Shares Outstanding		 42.87M 42.70M 52.23M 58.67M 58.87M 57.22M 59.34M 59.55M 59.67M 59.60M 61.75M
Diluted Earnings per Share		 ($0.49) ($0.54) ($0.35) ($0.32) ($0.41) ($0.43) ($0.47) ($0.47) ($0.50) ($0.57) ($0.64)
Weighted Average Diluted Shares Outstanding		 42.87M 42.70M 52.23M 58.67M 58.87M 57.22M 59.34M 59.55M 59.67M 59.60M 61.75M
Weighted Average Basic & Diluted Shares Outstanding		 43.06M 52.52M 52.54M 52.81M 50.60M 53.09M 53.18M 53.30M 53.37M 53.87M 59.47M

Annual Cash Flow Statements for Tyra Biosciences

This table details how cash moves in and out of Tyra Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 15 287 -50 -193 34 -15
Net Cash From Operating Activities		 -7.76 -24 -50 -50 -70 -95
Net Cash From Continuing Operating Activities		 -7.76 -24 -50 -50 -70 -95
Net Income / (Loss) Continuing Operations		 -9.34 -26 -55 -69 -86 -120
Consolidated Net Income / (Loss)		 -9.34 -26 -55 -69 -86 -120
Depreciation Expense		 0.05 0.14 0.30 0.36 0.52 0.55
Non-Cash Adjustments To Reconcile Net Income		 0.46 2.89 11 12 17 26
Changes in Operating Assets and Liabilities, net		 1.07 -0.48 -5.85 6.36 -0.73 -1.63
Net Cash From Investing Activities		 -0.31 -0.65 -0.56 -145 -98 72
Net Cash From Continuing Investing Activities		 -0.31 -0.65 -0.56 -145 -98 72
Purchase of Property, Plant & Equipment		 -0.31 -0.66 -0.56 -0.77 -0.66 -0.14
Purchase of Investments		 - - 0.00 -144 -264 -101
Sale and/or Maturity of Investments		 - - 0.00 0.00 166 174
Net Cash From Financing Activities		 23 311 0.63 1.54 202 8.10
Net Cash From Continuing Financing Activities		 23 311 0.63 1.54 202 8.10
Issuance of Common Equity		 0.14 182 0.63 1.54 202 8.10

Quarterly Cash Flow Statements for Tyra Biosciences

This table details how cash moves in and out of Tyra Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -17 -158 196 -155 4.40 -12 8.76 -2.23 -37 15 7.57
Net Cash From Operating Activities		 -17 -14 -22 -10 -18 -20 -25 -24 -22 -24 -33
Net Cash From Continuing Operating Activities		 -17 -14 -22 -10 -18 -20 -25 -24 -22 -24 -33
Net Income / (Loss) Continuing Operations		 -21 -23 -18 -19 -24 -26 -28 -28 -30 -34 -39
Consolidated Net Income / (Loss)		 -21 -23 -18 -19 -24 -26 -28 -28 -30 -34 -39
Depreciation Expense		 0.08 0.10 0.12 0.13 0.13 0.14 0.14 0.14 0.13 0.13 0.14
Non-Cash Adjustments To Reconcile Net Income		 4.38 2.94 2.89 2.54 5.97 5.52 5.56 5.67 7.16 7.50 7.82
Changes in Operating Assets and Liabilities, net		 -0.45 6.26 -6.84 5.77 0.02 0.32 -3.01 -1.39 0.20 2.58 -1.23
Net Cash From Investing Activities		 -0.08 -144 18 -145 22 6.96 32 21 -15 34 -120
Net Cash From Continuing Investing Activities		 -0.08 -144 18 -145 22 6.96 32 21 -15 34 -120
Purchase of Property, Plant & Equipment		 -0.08 -0.60 -0.14 -0.47 -0.05 -0.01 -0.01 -0.03 -0.04 -0.06 -0.09
Purchase of Investments		 - -144 -12 -177 -36 -38 -6.87 -20 -65 -9.11 -162
Sale and/or Maturity of Investments		 - - 30 33 58 45 39 41 50 44 42
Net Cash From Financing Activities		 0.47 0.32 200 0.37 0.74 0.71 2.19 0.58 0.65 4.68 160
Net Cash From Continuing Financing Activities		 0.47 0.32 200 0.37 0.74 0.71 2.19 0.58 0.65 4.68 160
Issuance of Common Equity		 0.47 0.32 200 0.37 0.74 0.71 2.19 0.58 0.65 4.68 160

Annual Balance Sheets for Tyra Biosciences

This table presents Tyra Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 16 307 266 226 364 283
Total Current Assets		 15 304 257 212 347 265
Cash & Equivalents		 15 302 251 58 92 77
Short-Term Investments		 - - 0.00 145 249 179
Prepaid Expenses		 0.06 1.88 6.08 8.20 6.02 9.45
Plant, Property, & Equipment, net		 0.30 1.03 1.08 1.63 1.65 1.31
Total Noncurrent Assets		 0.43 1.62 7.82 13 14 16
Other Noncurrent Operating Assets		 0.43 1.62 7.82 13 14 16
Total Liabilities & Shareholders' Equity		 16 307 266 226 364 283
Total Liabilities		 2.00 4.96 8.35 22 20 23
Total Current Liabilities		 1.86 3.62 5.70 15 15 18
Accounts Payable		 0.66 0.60 1.15 4.66 0.59 1.18
Accrued Expenses		 1.05 2.82 4.42 10 14 16
Other Current Liabilities		 0.14 0.20 0.14 0.28 0.41 0.47
Total Noncurrent Liabilities		 0.14 1.35 2.65 6.26 5.81 5.34
Other Noncurrent Operating Liabilities		 0.14 1.35 2.65 6.26 5.81 5.34
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -14 302 258 204 343 259
Total Preferred & Common Equity		 -14 302 258 204 343 259
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -14 302 258 204 343 259
Common Stock		 0.44 342 354 369 594 630
Retained Earnings		 -14 -40 -96 -165 -251 -371
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 0.38 0.77 0.39

Quarterly Balance Sheets for Tyra Biosciences

This table presents Tyra Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 276 255 250 238 405 392 381 343 321 302 412
Total Current Assets		 267 247 241 225 391 379 366 325 302 281 395
Cash & Equivalents		 263 242 232 216 254 99 104 101 98 62 85
Short-Term Investments		 - - - - 128 274 256 218 198 213 299
Prepaid Expenses		 4.26 5.01 8.33 8.98 8.32 4.78 5.48 5.62 5.88 6.29 11
Plant, Property, & Equipment, net		 1.15 1.05 1.05 1.15 1.59 1.90 1.79 1.52 1.41 1.35 1.22
Total Noncurrent Assets		 7.37 7.30 8.21 13 12 12 13 17 18 19 16
Other Noncurrent Operating Assets		 7.37 7.30 8.21 13 12 12 13 17 18 19 16
Total Liabilities & Shareholders' Equity		 276 255 250 238 405 392 381 343 321 302 412
Total Liabilities		 8.23 6.27 11 16 15 16 18 20 19 21 24
Total Current Liabilities		 5.49 3.68 5.41 10 8.72 10 12 14 14 16 19
Accounts Payable		 2.75 1.28 1.44 2.31 2.88 1.58 1.17 2.50 2.25 1.99 3.64
Accrued Expenses		 2.62 2.26 3.82 7.69 5.47 8.42 11 11 11 13 15
Other Current Liabilities		 0.13 0.14 0.14 0.15 0.37 0.38 0.40 0.43 0.44 0.46 0.49
Total Noncurrent Liabilities		 2.74 2.58 6.04 6.04 6.15 6.04 5.93 5.70 5.58 5.46 5.21
Other Noncurrent Operating Liabilities		 2.74 2.58 6.04 6.04 6.15 6.04 5.93 5.70 5.58 5.46 5.21
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 268 249 239 222 390 376 362 324 302 281 388
Total Preferred & Common Equity		 268 249 239 222 390 376 362 324 302 281 388
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 268 249 239 222 390 376 362 324 302 281 388
Common Stock		 351 356 359 364 573 578 586 602 609 617 798
Retained Earnings		 -83 -108 -121 -142 -183 -202 -226 -279 -308 -337 -411
Accumulated Other Comprehensive Income / (Loss)		 - - - - -0.01 -0.18 1.75 0.69 0.44 0.44 0.11

Annual Metrics And Ratios for Tyra Biosciences

This table displays calculated financial ratios and metrics derived from Tyra Biosciences' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 41,265,756.00 - - - 53,372,098.00
DEI Adjusted Shares Outstanding		 0.00 41,265,756.00 - - - 53,372,098.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -0.64 - - - -2.25
Growth Metrics		 - - - - - -
Profitability Metrics		 - - - - - -
Net Operating Profit after Tax (NOPAT)		 -6.51 -18 -41 -56 -73 -93
Return On Investment Capital (ROIC_SIMPLE)		 - - - -27.40% -21.25% -35.86%
Earnings before Interest and Taxes (EBIT)		 -9.34 -26 -59 -80 -104 -133
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.29 -26 -59 -80 -104 -132
Valuation Ratios		 - - - - - -
Leverage & Solvency		 - - - - - -
Liquidity Ratios		 - - - - - -
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -19 -48 -50 -74 -94
Efficiency Ratios		 - - - - - -
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -1.21 -0.45 6.62 0.79 1.71 3.17
Increase / (Decrease) in Invested Capital		 0.00 0.77 7.06 -5.82 0.92 1.46
Book Value per Share		 ($8.84) $7.31 $6.11 $4.74 $6.78 $4.86
Tangible Book Value per Share		 ($8.84) $7.31 $6.11 $4.74 $6.78 $4.86
Total Capital		 14 302 258 204 343 259
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -15 -302 -251 -203 -341 -256
Capital Expenditures (CapEx)		 0.31 0.65 0.56 0.77 0.66 0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.80 -1.74 0.37 -7.13 -8.57 -8.65
Debt-free Net Working Capital (DFNWC)		 13 300 252 196 333 247
Net Working Capital (NWC)		 13 300 252 196 333 247
Net Nonoperating Expense (NNE)		 2.83 7.89 14 13 14 27
Net Nonoperating Obligations (NNO)		 -15 -302 -251 -203 -341 -256
Total Depreciation and Amortization (D&A)		 0.05 0.14 0.30 0.36 0.52 0.55
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.91) ($1.32) ($1.62) ($1.51) ($2.01)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 41.60M 41.88M 42.70M 57.22M 59.60M
Adjusted Diluted Earnings per Share		 $0.00 ($1.91) ($1.32) ($1.62) ($1.51) ($2.01)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 41.60M 41.88M 42.70M 57.22M 59.60M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.91) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 13.78M 42.44M 52.52M 53.09M 53.87M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.51 -18 -41 -56 -73 -93
Debt Service Ratios		 - - - - - -
Payout Ratios		 - - - - - -

Quarterly Metrics And Ratios for Tyra Biosciences

This table displays calculated financial ratios and metrics derived from Tyra Biosciences' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - 53,089,957.00 53,177,990.00 53,297,140.00 53,372,098.00 53,867,115.00
DEI Adjusted Shares Outstanding		 - - - - - - 53,089,957.00 53,177,990.00 53,297,140.00 53,372,098.00 53,867,115.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -0.53 -0.53 -0.56 -0.63 -0.73
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Growth		 -76.13% -70.55% -55.78% -46.98% -19.25% -15.84% -42.82% -33.78% -15.23% - -32.02%
EBIT Growth		 -75.68% -70.30% -55.73% -46.95% -19.37% -15.94% -42.68% -33.66% -15.17% - -31.86%
NOPAT Growth		 -75.62% -70.67% -55.73% -46.95% -19.37% -15.94% -42.68% -33.66% -15.17% - -31.86%
Net Income Growth		 -69.09% -77.05% -53.13% -40.91% -13.54% -12.01% -54.72% -50.24% -24.37% - -39.64%
EPS Growth		 -63.33% -80.00% -25.00% -3.23% 16.33% 20.37% -34.29% -46.88% -21.95% - -36.17%
Operating Cash Flow Growth		 -40.39% -12.95% -123.70% -6.69% -4.39% -44.77% -15.57% -130.84% -25.04% - -27.94%
Free Cash Flow Firm Growth		 -2.35% 31.03% 13.47% 7.80% 16.45% -79.20% -22.04% -104.18% -69.11% - -48.53%
Invested Capital Growth		 43.41% -88.01% 4.63% -63.52% -66.89% 115.64% -38.10% 161.50% 158.80% - -10.50%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Q/Q Growth		 -49.95% -6.92% 13.05% -5.43% -21.67% -3.86% -7.21% 1.25% -4.79% - -15.05%
EBIT Q/Q Growth		 -49.64% -6.97% 12.92% -5.42% -21.55% -3.90% -7.17% 1.25% -4.74% - -15.01%
NOPAT Q/Q Growth		 -49.64% -6.97% 12.92% -5.42% -21.55% -3.90% -7.17% 1.25% -4.74% - -15.01%
Net Income Q/Q Growth		 -59.37% -7.93% 20.32% -2.80% -28.41% -6.47% -10.07% 0.17% -6.30% - -16.17%
EPS Q/Q Growth		 -58.06% -10.20% 35.19% 8.57% -28.13% -4.88% -9.30% 0.00% -6.38% - -12.28%
Operating Cash Flow Q/Q Growth		 -78.32% 21.07% -62.78% 53.43% -74.48% -9.45% -29.95% 6.98% 5.49% - -37.87%
Free Cash Flow Firm Q/Q Growth		 -37.62% 35.35% -31.62% 21.27% -24.70% -38.67% 10.37% -31.72% -3.28% - -7.00%
Invested Capital Q/Q Growth		 5.83% -87.83% 835.31% -69.70% -3.96% -20.76% 168.48% 27.99% -4.95% - 29.46%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Interest Burden Percent		 88.27% 89.06% 81.50% 79.47% 83.96% 86.04% 88.37% 89.34% 90.66% - 93.59%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -24.17% -29.92% -23.63% -26.32% -28.66% -31.60% -27.04% -31.21% -34.75% - -36.87%
Cash Return on Invested Capital (CROIC)		 -913.04% -1,353.45% -853.18% -1,496.64% -1,514.62% -5,900.19% -1,278.61% -2,185.56% -2,366.07% - -2,288.62%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Common Equity (ROCE)		 -24.17% -29.92% -23.63% -26.32% -28.66% -31.60% -27.04% -31.21% -34.75% - -36.87%
Return on Equity Simple (ROE_SIMPLE)		 -26.65% 0.00% -19.35% -21.51% -23.11% 0.00% -29.81% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -17 -18 -16 -16 -20 -21 -22 -22 -23 -26 -29
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.83% -2.15% -0.82% -0.74% -1.39% -1.75% -1.67% -1.82% -2.14% - -2.82%
Return On Investment Capital (ROIC_SIMPLE)		 - -8.78% - - - -6.06% -6.89% -7.29% -8.22% -9.86% -7.59%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -24 -26 -22 -24 -29 -30 -32 -31 -33 -37 -42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -24 -26 -22 -23 -28 -30 -32 -31 -33 -36 -42
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.67 2.92 2.21 2.23 3.43 2.05 1.53 1.68 2.66 - 5.32
Price to Tangible Book Value (P/TBV)		 2.67 2.92 2.21 2.23 3.43 2.05 1.53 1.68 2.66 - 5.32
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 57.78 495.45 64.57 207.53 408.41 211.66 38.07 36.19 84.28 - 408.77
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -0.98 -0.98 -0.98 -0.99 -0.99 -1.00 -0.98 -0.99 -0.99 - -0.99
Leverage Ratio		 1.05 1.06 1.03 1.05 1.06 1.08 1.05 1.05 1.06 - 1.06
Compound Leverage Factor		 0.93 0.95 0.84 0.83 0.89 0.93 0.93 0.94 0.96 - 0.99
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 21.87 16.22 35.09 30.91 40.73 20.54 14.49 15.19 20.09 - 49.96
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 22.14 13.80 44.83 36.46 29.55 23.81 22.78 21.94 17.71 - 20.49
Quick Ratio		 21.25 13.27 43.88 36.00 29.11 23.40 22.39 21.52 17.31 - 19.91
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -19 -12 -16 -13 -16 -22 -19 -26 -26 -27 -29
Operating Cash Flow to CapEx		 -20,656.63% -2,244.11% -16,197.06% -2,182.55% -34,419.23% -326,500.00% -181,842.86% -76,387.10% -57,384.62% - -37,012.50%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 6.52 0.79 7.42 2.25 2.16 1.71 4.59 5.88 5.59 3.17 4.11
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Increase / (Decrease) in Invested Capital		 1.97 -5.82 0.33 -3.91 -4.36 0.92 -2.83 3.63 3.43 1.46 -0.48
Enterprise Value (EV)		 377 393 479 466 881 362 175 213 471 - 1,680
Market Capitalization		 592 596 861 840 1,241 703 494 509 746 - 2,063
Book Value per Share		 $5.17 $4.74 $7.42 $7.16 $6.86 $6.78 $6.09 $5.68 $5.26 $4.86 $7.20
Tangible Book Value per Share		 $5.17 $4.74 $7.42 $7.16 $6.86 $6.78 $6.09 $5.68 $5.26 $4.86 $7.20
Total Capital		 222 204 390 376 362 343 324 302 281 259 388
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -216 -203 -382 -374 -360 -341 -319 -296 -275 -256 -383
Capital Expenditures (CapEx)		 0.08 0.60 0.14 0.47 0.05 0.01 0.01 0.03 0.04 0.06 0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.17 -7.13 -0.40 -5.60 -6.89 -8.57 -8.62 -7.89 -9.59 -8.65 -8.11
Debt-free Net Working Capital (DFNWC)		 214 196 382 368 353 333 310 288 265 247 375
Net Working Capital (NWC)		 214 196 382 368 353 333 310 288 265 247 375
Net Nonoperating Expense (NNE)		 4.38 4.89 2.57 2.23 3.99 4.77 5.85 6.08 6.81 8.27 9.91
Net Nonoperating Obligations (NNO)		 -216 -203 -382 -374 -360 -341 -319 -296 -275 -256 -383
Total Depreciation and Amortization (D&A)		 0.08 0.10 0.12 0.13 0.13 0.14 0.14 0.14 0.13 0.13 0.14
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.49) ($0.54) ($0.35) ($0.32) ($0.41) ($0.43) ($0.47) ($0.47) ($0.50) ($0.57) ($0.64)
Adjusted Weighted Average Basic Shares Outstanding		 42.87M 42.70M 52.23M 58.67M 58.87M 57.22M 59.34M 59.55M 59.67M 59.60M 61.75M
Adjusted Diluted Earnings per Share		 ($0.49) ($0.54) ($0.35) ($0.32) ($0.41) ($0.43) ($0.47) ($0.47) ($0.50) ($0.57) ($0.64)
Adjusted Weighted Average Diluted Shares Outstanding		 42.87M 42.70M 52.23M 58.67M 58.87M 57.22M 59.34M 59.55M 59.67M 59.60M 61.75M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 43.06M 52.52M 52.54M 52.81M 50.60M 53.09M 53.18M 53.30M 53.37M 53.87M 59.47M
Normalized Net Operating Profit after Tax (NOPAT)		 -17 -18 -16 -16 -20 -21 -22 -22 -23 -26 -29
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Tyra Biosciences (TYRA) continues to operate without revenue, posting meaningful net losses and cash burn. The company has relied on equity financing and investment activity to fund its R&D programs, and 2025 shows both liquidity support and ongoing fundraising. Below are the key trends drawn from quarterly statements over the past four years, focused on liquidity, capital activity, and profitability signals for retail investors.

  • Liquidity: As of 2025 Q3, Tyra held about $61.95M in cash and $212.97M in short-term investments, totaling roughly $274.9M of readily available liquidity on the balance sheet.
  • Ongoing equity financing: In 2025, Tyra raised roughly $8.1M in net proceeds from common stock issuances across Q1–Q4 2025 (Q1: $2.19M; Q2: $0.58M; Q3: $0.65M; Q4: $4.68M).
  • Investing activity inflows: Tyra has benefited from sizable cash inflows from sale/maturity of investments in several quarters, including Q2 2025 ($41.00M), Q3 2025 ($50.41M), and Q4 2025 ($43.54M), which bolster liquidity during periods of negative operating cash flow.
  • Net financing activity: In select quarters, net financing activity contributed to liquidity (e.g., Q4 2025 net financing activity around $4.68M; Q1 2025 around $2.19M), helping support cash on hand during funding gaps.
  • Balance sheet strength: Total assets around $301.9M (2025 Q3), with total liabilities about $21.3M and total equity around $280.5M, indicating a sizable equity base and relatively light leverage vs. assets.
  • Revenue status: Tyra remains pre-revenue in many quarters, with Total Revenue reported as $0 in Q4 2025 and in several prior periods, reflecting a development-stage biotech profile rather than a sales-driven model.
  • Dilution risk: Continued equity issuances and a relatively high share count contribute to potential dilution concerns; 2025 quarters show weighted-average basic/diluted shares in the 59–60 million range for 2025 Q4, producing negative EPS despite no revenue.
  • Persistent net losses: Net income attributable to common shareholders in 2025 Q4 is -$33.834M; 2025 Q3 is -$29.868M; Q2 is -$28.098M; Q1 is -$28.147M, highlighting ongoing losses as funds are directed to R&D and clinical programs.
  • Operating cash burn: Net cash from operating activities remained negative across observed 2025 quarters (e.g., Q4 2025: -$23.624M; Q3 2025: -$22.38M; Q2 2025: -$23.68M; Q1 2025: -$25.46M), indicating a continued need for external funding.
  • Deficit in retained earnings: Retained earnings are deeply negative (e.g., Q4 2025 balance sheet Retained Earnings: -$337.424M), reflecting accumulated losses that must be funded through future financing or equity value realization.
05/25/26 04:34 PM ETAI Generated. May Contain Errors.

Tyra Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Tyra Biosciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Tyra Biosciences' net income appears to be on an upward trend, with a most recent value of -$119.95 million in 2025, rising from -$9.34 million in 2020. The previous period was -$86.48 million in 2024. See Tyra Biosciences' forecast for analyst expectations on what's next for the company.

Tyra Biosciences' total operating income in 2025 was -$132.76 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $132.76 million

Over the last 5 years, Tyra Biosciences' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

Tyra Biosciences' total liabilities were at $23.43 million at the end of 2025, a 14.8% increase from 2024, and a 1,072.8% increase since 2020.

In the past 5 years, Tyra Biosciences' cash and equivalents has ranged from $15.22 million in 2020 to $302.18 million in 2021, and is currently $77.39 million as of their latest financial filing in 2025.

Over the last 5 years, Tyra Biosciences' book value per share changed from -8.84 in 2020 to 4.86 in 2025, a change of -154.9%.


Related Companies

Financial statements for NASDAQ:TYRA last updated on 5/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Goldman Sachs just told you what to buy (most people missed it)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The AI stocks about to become worthless (and one that isn't)
Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...
InvestorPlace | Sponsoredtc pixel
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel